Therapeutic Approach

Archive: June, 2019

Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

LOS ANGELES (June 20, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first Food and Drug Administration (FDA)-approved […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD